Background: Treatment with the IL-12/23 antibody ustekinumab produces a satisfactory response (i.e., 75% reduction in psoriasis area and severity index [PASI75]) in the majority of patients with moderate to severe chronic plaque-type psoriasis.
Objectives: To determine whether concomitant 311-nm UVB can further enhance the response in psoriasis patients treated with ustekinumab.
Methods: Ten patients (5 women; 5 men; mean age, 58 years; range, 48 to 66 years) with moderate to severe plaque-type psoriasis were treated with ustekinumab at a standard dosage of 45 or 90 mg s.c. depending on body weight (below ...
311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial is a post from: Skincare
311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial via BuzzBlazer.com
No comments:
Post a Comment